Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Qun Dang is active.

Publication


Featured researches published by Qun Dang.


Journal of Medicinal Chemistry | 2017

Hit-to-Lead Optimization and Discovery of 5-((5-([1,1′-Biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic Acid (MK-3903): A Novel Class of Benzimidazole-Based Activators of AMP-Activated Protein Kinase

Ping Lan; F. Anthony Romero; Dariusz Wodka; Andrew J. Kassick; Qun Dang; Tony S. Gibson; Daniel K. Cashion; Gaochao Zhou; Yuli Chen; Xiaoping Zhang; Aihua Zhang; Ying Li; Maria E. Trujillo; Qing Shao; Margaret Wu; Shiyao Xu; Huaibing He; Deidre A. MacKenna; Jocelyn Staunton; Kevin T. Chapman; Ann E. Weber; Iyassu K. Sebhat; Gergely M. Makara

AMP-activated protein kinase (AMPK) plays an essential role as a cellular energy sensor and master regulator of metabolism in eukaryotes. Dysregulated lipid and carbohydrate metabolism resulting from insulin resistance leads to hyperglycemia, the hallmark of type 2 diabetes mellitus (T2DM). While pharmacological activation of AMPK is anticipated to improve these parameters, the discovery of selective, direct activators has proven challenging. We now describe a hit-to-lead effort resulting in the discovery of a potent and selective class of benzimidazole-based direct AMPK activators, exemplified by 5-((5-([1,1-biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic acid, 42 (MK-3903). Compound 42 exhibited robust target engagement in mouse liver following oral dosing, leading to improved lipid metabolism and insulin sensitization in mice.


Archive | 2012

Chapter 11:The Discovery and Development of MB07803, a Second-Generation Fructose-1,6-bisphosphatase Inhibitor with Improved Pharmacokinetic Properties, as a Potential Treatment of Type 2 Diabetes

Qun Dang; Paul D. van Poelje; Mark D. Erion

Type 2 diabetes (T2DM) is a chronic disease affecting 346 million people worldwide, with the World Health Organization projecting that diabetes-related deaths will double between 2005 and 2030. Hyperglycemia is one of many hallmarks for T2DM, which is associated with an increased risk of nephropathy...


Nucleosides, Nucleotides & Nucleic Acids | 2016

2′-Modified Guanosine Analogs for the Treatment of HCV

Girijavallabhan; Ashok Arasappan; Frank Bennett; Chen K; Qun Dang; Huang Y; Angela Kerekes; Nair L; Pissarnitski D; Verma; Alvarez C; Chen P; Cole D; Esposite S; Hong Q; Liu Z; Pan W; Pu H; Rossman R; Truong Q; Vibulbhan B; Wang J; Zhao Z; Olsen D; Stamford A; Stephane Bogen; Njoroge Fg

ABSTRACT Novel 2′-modified guanosine nucleosides were synthesized from inexpensive starting materials in 7–10 steps via hydroazidation or hydrocyanation reactions of the corresponding 2′-olefin. The antiviral effectiveness of the guanosine nucleosides was evaluated by converting them to the corresponding 5′-O-triphosphates (compounds 38–44) and testing their biochemical inhibitory activity against the wild-type NS5B polymerase.


Archive | 2012

2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases

Vinay Girijavallabhan; F. George Njoroge; Stephane Bogen; Angela Kerekes; Frank Bennett; Ying Huang; Latha G. Nair; Dmitri Pissarnitski; Vishal Verma; Qun Dang; Ian W. Davies; David B. Olsen; Andrew W. Stamford; Joseph P. Vacca


Archive | 2015

ANTIDIABETIC TRICYCLIC COMPOUNDS

William K. Hagmann; Ravi P. Nargund; Timothy A. Blizzard; Hubert Josien; Purakkattle Biju; Christopher W. Plummer; Qun Dang; Bing Li; Linus S. Lin; Mingxiang Cui; Bin Hu; Jinglai Hao; Zhengxia Chen


Archive | 2012

2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

Vinay Girijavallabhan; F. George Njoroge; Stephane Bogen; Frank Bennett; Vishal Verma; Ashok Arasappan; Kevin X. Chen; Ying Huang; Angela Kerekes; Latha G. Nair; Dimitri Pissarnitski; Qun Dang; Ian W. Davies; David B. Olsen; Andrew W. Stamford; Joseph P. Vacca


Archive | 2012

5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases

Vishal Verma; Ashok Arasappan; F. George Njoroge; Vinay Girijavallabhan; Stephane L. Bogen; Qun Dang; David B. Olsen


Archive | 2014

2'-DISUBSTITUTED SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

Vinay Girijavallabhan; Stephane Bogen; Weidong Pan; Qun Dang; Ian W. Davies


Tetrahedron Letters | 2013

A general approach to substituted 6H-pyrido[2′,3′:5,6] [1,3]oxazino[3,4-a]indole via cyclization from an indoline precursor followed by re-aromatization

Shuwen He; Peng Li; Xing Dai; Casey Cameron Mccomas; Hongling Huang; Chaoliang Zhan; Liang Chang; Yuehui Liu; Shaojun Chen; Zhong Lai; Hong Liu; Jingjun Yin; Qun Dang; Dong Xiao; Nicolas Zorn; Xuanjia Peng; Ravi P. Nargund; Anandan Palani


Tetrahedron Letters | 2014

Syntheses of 4′-spirocyclic phosphono-nucleosides as potential inhibitors of hepatitis C virus NS5B polymerase

Qun Dang; Zhibo Zhang; Shuangsheng He; Yaohong Liu; Tongqian Chen; Stephane Bogen; Vinay Girijavallabhan; David B. Olsen; Peter T. Meinke

Collaboration


Dive into the Qun Dang's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ravi P. Nargund

Albany Molecular Research

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge